GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA
Pharmaceutical Technology
FEBRUARY 23, 2023
This collaboration is expected to help expedite the clinical manufacturing of RVM-V001 and future mRNA-based vaccines that target infectious diseases such as Clostriodioides difficile infection (CDI) and Respiratory syncytial virus (RSV). RVAC Medicines CEO Dr Sean Fu said: “We are excited to work closely with GenScript ProBio.
Let's personalize your content